Diary - News All news Medesis Pharma and Transgene collaborate to explore the contribution of the Aonys® platform

Medesis Pharma and Transgene collaborate to explore the contribution of the Aonys® platform

Medesis Pharma and Transgene collaborate to explore the contribution of the Aonys® platform to oncolytic virotherapies

July 8, 2019 – MEDESIS PHARMA announces the signing of a collaborative research agreement with TRANSGENE to apply Aonys® technology to the treatment of tumors by oncolytic viruses. This collaboration allows testing of an innovative approach of modulating the tumoral microenvironment, and thus increasing the oncolytic viruses’ activity and their field of use.

Read the press release

Headlines

Our members

The MAGIA MedTech Alliance and FBRI build new connections Between Japan and Europe by signing a Joint collaboration agreement

March 22^th, 2022

Lys Therapeutics and Inserm Transfert sign a three-year agreement

March 4^th, 2022

Adocia renforce sa trésorerie de 19 millions d’euros à la suite d’une opération immobilière

March 29^th, 2022

All news

Medesis Pharma and Transgene collaborate to explore the contribution of the Aonys® platform